ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million,.
/PRNewswire/ Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies.
/PRNewswire/ Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies.
North American Morning Briefing: Stock Futures -2- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.